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Structural bioinformaticsRhodopsin, the dim-light photoreceptor present in the rod cells of the retina, is both a retinal-binding protein and
a G protein-coupled receptor (GPCR). Due to this conjunction, it beneﬁts from an arsenal of spectroscopy tech-
niques that can be used for its characterization, while being a model system for the important family of Class A
(also referred to as “rhodopsin-like”) GPCRs. For instance, rhodopsin has been a crucial player in the ﬁeld of
GPCR structural biology. Until 2007, it was the only GPCR for which a high-resolution crystal structurewas avail-
able, so all structure–activity analyses on GPCRs, from structure-based drug discovery to studies of structural
changes upon activation, were based on rhodopsin. At present, about a third of currently available GPCR struc-
tures are still from rhodopsin. In this review, I show some examples of how these structures can still be used
to gain insight into general aspects of GPCR activation. First, the analysis of the third intracellular loop in rhodop-
sin structures allows us to gain an understanding of the structural and dynamic properties of this region, which is
absent (due to protein engineering or poor electron density) in most of the currently available GPCR structures.
Second, a detailed analysis of the structure of the transmembrane domains in inactive, intermediate and active
rhodopsin structures allows us to detect early conformational changes in the process of ligand-induced GPCR
activation. Finally, the analysis of a conserved ligand-activated transmission switch in the transmembrane bundle
of GPCRs in the context of the rhodopsin activation cycle, allows us to suggest that the structures of many of the
currently available agonist-bound GPCRs may correspond to intermediate active states. While the focus in GPCR
structural biology is inevitably moving away from rhodopsin, in other aspects rhodopsin is still at the forefront.
For instance, the ﬁrst studies of the structural basis of disease mutants in GPCRs, or the most detailed analysis
of cellular GPCR signal transduction networks using a systemsbiology approach, have been carried out in rhodop-
sin. Finally, due again to its unique properties among GPCRs, rhodopsin will likely play an important role in the
application of X-ray free electron laser crystallography to time-resolved structural biology inmembrane proteins.
Rhodopsin, thus, still remains relevant as amodel system to study themolecularmechanisms of GPCR activation.
This article is part of a Special Issue entitled: Retinal Proteins—You can teach an old dog new tricks.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Thanks to innovative protein engineering techniques and crystallog-
raphy methods [1,2], from 2007 there has been an almost exponential
growth in the number of available G protein-coupled receptor (GPCR)
structures [3]. While this has provided unprecedented insights into
the structural and functional diversity of this protein family, it is becom-
ing increasingly more difﬁcult to identify common features that allow
us to derive the general aspects of GPCR function. This is especially
true as most of these new structures have required heavy protein
engineering to yield crystallizable proteins, such as removal of post-
translational modiﬁcations, truncations of ﬂexible regions, creation of
fusion chimeras, addition of thermostabilizing mutations or the use of
antibodies. The only exception is still rhodopsin,whichhas been crystal-
lized with its full sequence including the third intracellular loop and theProteins—You can teach an old
ights reserved.C-terminus, and in a native form or with minimal modiﬁcations.
Rhodopsin is also remarkable in other aspects. For instance, all Class A
non-rhodopsin GPCR structures so far have been solved by molecular
replacement and are thus ultimately based on the ﬁrst structure of
rhodopsin [4]. Rhodopsin further yielded the ﬁrst structure of a recom-
binant GPCR produced in mammalian cells, and the ﬁrst solved using
microcrystallographic techniques. The combination of these two factors
opened the revolution in GPCR structural biology thatwe are experienc-
ing nowadays.
There are currently 25 structures of eukaryotic rhodopsins deposited
in the Protein Data Bank (Table 1), which account roughly to 1/3 of all
the GPCR structures available. The majority of these structures (21)
are from bovine rhodopsin. Of these, 10 correspond to inactive states
(i.e. dark states bound to 11-cis or 9-cis retinal), 8 correspond to active
states (light-activated or obtained by soaking all-trans retinal in opsin
crystals) and, importantly, 3 structures correspond to activation inter-
mediates (bathorhodopsin, lumirhodopsin and a deprotonated inter-
mediate). There is also a low resolution electron density map of an
additional intermediate, metarhodopsin I [5]. In addition, there are 4
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Fig. 1. GPCR crystal structures with solved ICL3. In the β1 and β2 adrenergic receptors the
loop was truncated for crystallography, while squid and bovine rhodopsin, and the aden-
osine A2A receptor feature the full-length native loop. In all cases, most of ICL3 forms an
extension of TM5 and TM6, that can extend up to 24 Å into the cytoplasm. The structures
of dark (inactive) and light-activated (active) rhodopsin (boxed) allow the visualization of
the conformational changes in this loop associated to receptor activation.
676 X. Deupi / Biochimica et Biophysica Acta 1837 (2014) 674–682structures of squid rhodopsin: 3 inactive and one intermediate active
state (bathorhodopsin). Thus, rhodopsin is the GPCR for which we pos-
sess a richer structural information about the activation intermediates,
and much can be learned about the general aspects of GPCR activation
by analyzing these structures.
Identiﬁcation of structural intermediates has been aided by the de-
tailed spectroscopic characterization of the rhodopsin activation cycle
by UV–VIS and FTIR spectroscopy (see [6] for a review). Once identiﬁed,
rhodopsin intermediate states can be stabilized by, for instance,
adjusting temperature and pH, which allowed their characterization
using a variety of techniques (e.g. site-directed labeling methods
coupled with spin-labeling EPR [7], double electron–electron resonance
(DEER) [8] or ﬂuorescence [9] spectroscopy) and, ultimately, their crys-
tallization and structure determination [10–12]. NMR spectroscopy in
GPCRs was also pioneered in rhodopsin. For instance, solid-state NMR
has been used to characterize conformational changes in the retinal
binding pocket [13] and in the cytoplasmic side of rhodopsin [14], or
the dynamic properties of retinal [15] during different states in the acti-
vation process (see [16] for a review).
The possibility to trigger activation by photoisomerization of retinal
allows a ﬁne control in the experimental set-up of such assays. Such
property, however, is not strictly restricted to rhodopsin, as there
exist “caged” compounds (e.g. 2-nitrobenzyl derivatives of adrenergic
ligands [17,18]) that can be converted into agonists using light. Thus,
photoactivation of non-rhodopsin GPCRs, in combination with, for in-
stance, FTIR or NMR spectroscopy (as it has been done in the glutamate
receptor [19], Ca2+-ATPase [20] and Ras [21]), could also be used in the
future to monitor ligand-induced conformational changes in a wider
range of GPCRs. However, non-rhodopsin GPCR intermediate states
are usually stabilized using pharmacological tools (e.g. inverse, partial
or biased agonists). In recent years, some aspects of such conformation-
al states in the β2 adrenergic receptor, such as ligand-speciﬁc structural
changes around in the extracellular domains [22], structural plasticity in
transmembrane helix 6 (TM6) and TM7 related to biased agonism [23],
and the existence of conformational states not observed in crystal struc-
tures [24,25], have been characterized by NMR spectroscopy.
The unique properties of rhodopsinsmake them valuable systems to
study the molecular details of intermediates in the GPCR activation
pathway. In this review, I will discuss three examples of how rhodopsin
structures can be used to gain insight into general aspects of the dynam-
ics of GPCR activation. First, the analysis of the third intracellular loop in
bovine rhodopsin structures allows us to gain insight into the ﬂexibility
and dynamic properties of this region, absent in most of the available
GPCR structures. Comparison with squid rhodopsin and human adeno-
sine A2A receptor suggests the presence of secondary structure in the N-
and C-terminal domains of this loop. Second, a detailed structural anal-
ysis of TM2 and TM3 in inactive, intermediate and active rhodopsin
structures allows us to detect early conformational changes that consti-
tute the ﬁrst steps in an activation pathway through TM7, and may be
related to the phenomenon of biased signaling in non-rhodopsin
GPCRs. Finally, the analysis of a conserved feature of agonist-bound
GPCR structures (activation of a transmission switch in the TM3–
TM5–TM6 interface) in the context of the rhodopsin activation cycle,
allows us to suggest that these structuresmay correspond to intermedi-
ate active states.
2. Structure of the third intracellular loop in GPCR crystal structures
The third intracellular loop (ICL3), joining the cytoplasmic sides of
TM5 and TM6 and involved in binding and activation of cytoplasmic
partners, is highly variable in length in human rhodopsin-like GPCRs
(126 ± 114 amino acids [26]). In many receptors, this region is likely
intrinsically disordered [27], which would allow regulation of protein–
protein recognition by exposure of linear peptide motifs [28]. Such
long and ﬂexible regions may preclude formation of ordered protein
crystals and, thus, despite their functional relevance, they are oftenengineered for structural studies. For instance, inmanyGPCR constructs
for crystallography, ICL3 was substituted by a conformationally stable
soluble protein (T4 lysozyme [29] or apocytochrome b(562)RIL [30]).
While these fusion proteins have paved theway for the great recent ad-
vances in GPCR crystallography, they inherentlymask the structural and
functional properties of the cytoplasmic side of the receptor. As an alter-
native strategy, in some receptors ICL3 has been truncated to reduce the
conformational heterogeneity of the protein construct. While initially
these shortened loops featured very low electron density, more recent
structures have been able to solve its structure, e.g. in the β1 [31] and
β2 adrenergic receptors [32] (Fig. 1). Interestingly, in the case of the β1
adrenergic receptor, two distinct conformations of the cytoplasmic
side of TM6 and ICL3were observed, which has been suggested to be in-
volved in the basal activity of the receptor [31]. Themost compelling ev-
idence of the role of ICL3 in the interaction with intracellular partners
comes from the crystal structure of the complex between the β2 adren-
ergic receptor and Gs [33]. The receptor construct contains the full ICL3
sequence (54 residues [34]), which, in the crystal structure, forms a
helical extension of TM5 (~3 helix turns) and TM6 (~4 helix turns)
joined by a disordered (and not visible) stretch of 26 amino acids. In
this case, the resolved region of TM5 protrudes ~21 Å into the cyto-
plasm, similarly to squid rhodopsin or the A2A receptor (Fig. 1).
To date, only three GPCRs have been solvedwith a visible native full-
length ICL3: bovine and squid rhodopsin (see Table 1) and the adeno-
sine A2A receptor [35,36] (Fig. 1).
The structures of inactive dark-state bovine rhodopsin provide valu-
able information about the putative structural ﬂexibility of ICL3. While
this loop is relatively short (26 residues; Leu226–Thr251 [34]), it fea-
tures two different conformations. In the trigonal crystal form (PDB id:
1GZM, 2J4Y, 2I35 and 2I36), TM5 and TM6 extend 10 and 16 Å respec-
tively into the cytoplasm, and are joined by a short 11 residue “arch”
(Fig. 1). On the other hand, in the tetragonal crystal form TM5 only ex-
tends 6 Å into the cytoplasm, and the unstructured segment joining the
helices “folds back” towards the membrane. In both crystal forms, ICL3
points into a solvent channel and is not responsible for crystal packing.
Also, the high B-factors of this region have been proposed to correspond
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these conformations result from the inherent structural ﬂexibility of
ICL3, and can be present in a biological environment. Upon activation,
the cytoplasmic side of TM5 straightens and elongates approximately
6 additional Å (Fig. 1, box), resulting in a marked shortening of stretch
joining the helical segments of ICL3. This active conformation of ICL3
is common to the structures of active opsin at low pH, active opsin
soaked with all-trans retinal and light-activated rhodopsin mutants, in
the presence and absence of stabilizing GαCT peptides. Thus, it seems
likely that these new structures of ICL3 correspond to the biological con-
formation in the Meta II active state.
The structure of squid rhodopsin [38] revealed that TM5 and TM6
could prolong even further beyond the cell membrane. In this case,
the longer ICL3 (32 residues) extends 24 Å into the cytoplasm, as two
helical stretches of ~4 turns joined by a short stretch of ~6 residues
(Fig. 1). Such fold is also present in several recent structures of the A2A
receptor (thermostabilized by alanine mutagenesis [35] and bound to
an allosteric inverse agonist antibody [36]) (Fig. 1), although in a
slightly different orientation. Thus, despite that we still have a limited
structural information about this region, it seems likely that the helical
segments forming N- and C-terminal parts of ICL3 (i.e. the extensions
of TM5 and TM6 into the cytoplasm) are a common feature among
GPCRs. Interestingly, an NMR structure of ICL3 of the vasopressin V2
receptor [39] shows that this “loop” also is formed by two long alpha he-
lices, which are proposed to be extensions of TM5 and TM6 that pro-
trude into the cytoplasm, joined by a short arginine-rich loop of
higher mobility.
In summary, ICL3 is key to understand the structural basis of the
interaction between GPCRs and intracellular partners (e.g. G proteins,
kinases and arrestins). Currently, our knowledge of full-length native
ICL3 structures is limited to rhodopsins and, recently, the A2A receptor.
These structures, thus, constitute valuable templates for homology
modeling of ICL3, either in receptors of unknown structure, or in
currently available structures where this loop has been substituted by
a fusion partner. It is important to remember that in many cases ICL3
can be much longer than in the available templates: e.g. 150–200 resi-
dues in the recently crystallizedM2 [40] andM3 [41] muscarinic recep-
tors. In addition, these long loops can be intrinsically disordered [42].
Despite these drawbacks, our current knowledge of the structure of
ICL3 can still be used to gain insight into the details of GPCR activation,
particularly in receptors of relatively short (b50 residues) ICL3 (e.g. V2
vasopressin or neurotensin NTS1 receptors). For instance, the NMR
structure of ICL3 of the V2 vasopressin receptor [39] and the structure
of squid rhodopsin [38] were used to model the cytoplasmic region of
the vasopressin V2 receptor and interpret ﬂuorescence spectroscopy
data to gain insight into the structural basis of biased signaling [43].
3. Early conformational changes in GPCR activation
The crystal structures of rhodopsin revealed that the transmem-
brane segments in GPCRs were far from being ideal α-helices. Also,
while the presence of highly conserved Pro residues in TM5, TM6 and
TM7 suggested that these helices were kinked, they do not resemble
“standard” Pro-kinked helices either, but present very strong localized
structural distortions [44]. Among the methods to quantify distortions
in protein structures, HelAnal [45] provides local bend and opening/
tightening (twist) values for each helix turn.
Fig. 2 shows the proﬁles of helix bend and twist for TM2 and TM3 in
the structures of inactive (red), bathorhodopsin and lumirhodopsin
(orange) and active (yellow) states of rhodopsin. While TM3 is a fairly
regular α-helix (unit twist around 100° and low local bend angles),
TM2 presents a strong bend and helix opening (decrease in unit twist)
at Gly89(2.56)-Gly90(2.57) (the numbers in parenthesis denote the
residue position in the Ballesteros–Weinstein scheme [46]). In the inac-
tive state, this local distortion is stabilized by an unusual intrahelical
hydrogen bond network [47] and possibly by a water molecule, asobserved in the structure of lumirhodopsin [11]. This local distortion is
translated in an overall bend of ~30° in TM2 towards TM1 and away
from TM3 [37].
Upon light activation, retinal isomerization results in an increase in
the volume of the binding pocket, already in lumirhodopsin, primarily
due to the relocation of the Met207(5.42) side chain [48]. However,
the most noticeable structural changes in the backbone occur in TM2
(around Gly89(2.56)-Gly90(2.57)) and TM3 (around G114(3.29) and
G120(3.35)-G121(3.36)) [11] in the transition from bathorhodopsin to
lumirhodopsin (Fig. 2). These structural changes can be visualized as a
local increase in the helix bend (10–20°) in TM2 and TM3 (compare
red vs. orange lines). In both cases, these distortions relax in the transi-
tion to the Meta II state (compare orange vs. yellow lines). The local
structural rearrangement at the backbone of Gly89(2.56)-Gly90(2.57)
in lumirhodopsin also correlates with the change of the side chain con-
formation of Met86(2.53). In human rhodopsin-like GPCRs, position
2.53 contains 81% of bulky/aromatic residues. In addition, an evolution-
ary trace analysis in rhodopsin-like GPCRs identiﬁedMet86(2.53) in the
top 20% of important conserved positions [49]. Application of this tech-
nique to bioamine receptors leads us to suggest that this position may
communicate with Trp(6.48) through intervening water molecules
that occupy a cavity in the structure [50]. Thus, the early structural
changes in TM2 at the level of the binding pocket observed in the
lumirhodopsin state, together with the change in the side chain confor-
mation of Met86(2.53), may be the ﬁrst stage of an activation pathway
through TM2/TM7 [51], which is ampliﬁed in later stages. InMeta II, the
larger movements in TM6 and TM7 weaken the packing between TM2,
TM3, TM6 and TM7, mediated by Met86(2.53), Gly121(3.36),
Trp265(6.48) and Ser298(7.45), which opens a passage connecting
the ligand binding pocket to the cytoplasmic side of the transmembrane
bundle (Fig. 3) [52]. This, combined with the opening of a cytoplasmic
hydrophobic barrier [53], allows the relocation of a cluster of intramo-
lecular water molecules, which creates a new set of hydrogen bond
interactions that stabilize the active state. Relocation of these waters is
directly translated into a remarkable conformational change in TM7, a
key feature of the active state.
While Gly89(2.56)-Gly90(2.57) are conserved only in rhodopsin
vertebrate type 1 GPCRs, other rhodopsin-like GPCRs feature Pro resi-
dues at the 2.57, 2.58, 2.59 and 2.60 positions with different patterns
of conservation in different subfamilies [47]. In the currently available
crystal structures, a variety of sequence motifs stabilize different local
structures that are key to shape the binding pocket. Interestingly, the
extracellular side of TM2 is key for ligand-induced activation in several
GPCRs, and has been suggested to be involved in biased signaling [54].
Thus, while some aspects of the above activation mechanism may be
speciﬁc to rhodopsin, the existence of a signal transduction pathway
that connects ligand-induced local conformational changes in TM2 (as
observed in lumirhodopsin) with larger structural changes in TM7
may be a conserved feature of rhodopsin-like GPCRs.
4. Structures of agonist-bound GPCRs as intermediates in the
activation pathway
GPCRs exist not only in a dual inactive/active state, but in an
ensemble of conformations [55], which, in many cases, contains a
small population of active states even in the absence of activating sig-
nals [56]. Activation can then be depicted as shifts in the population of
these discrete conformational intermediates [57]. In several GPCRs,
such intermediates have been detected by, for instance, ﬂuorescence
spectroscopy [43,56], NMR [24] or ﬂuorescence resonance energy trans-
fer [58]. However, most of our knowledge of the intermediate states in
GPCR activation has originated from rhodopsin (see [6] for a compre-
hensive review), where such metastable intermediates can be charac-
terized by spectroscopic methods (UV–VIS and FTIR spectroscopy).
The crystal structures of bathorhodopsin [10,12], lumirhodopsin [11]
and the electron crystallography map of Meta I [5] revealed that there
Fig. 2. Left panel: local bend andunit twist proﬁles for TM2 (top) and TM3(bottom) in the crystal structures of rhodopsin. The horizontal black line in the twist proﬁles depicts the value for
an ideal α-helix (100°). A decrease in twist corresponds to a local opening in the helix. The strongest distortions and changes upon activation are localized near the Gly residues in these
helices (gray boxes). Right panel: difference in local bend between dark inactive rhodopsin and lumirhodopsin plotted on the structure of lumirhodopsin (blue—no difference; red—
highest difference). Themain structural changes in the early stages of activation are foundat theGly89(2.56)-Gly90(2.57)motif in TM2, and nearMet86(2.53) (blue sticks),which changes
conformation during the transition to the lumirhodopsin state.
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small local rearrangements in the retinal binding site. Also, an FTIR spec-
troscopy analysis of rhodopsin incorporating genetically encoded infra-
red probes [59] shows only small-scale structural changes in the
cytoplasmic side in the transition from Lumi toMeta I, consisting in a ro-
tation of TM6 and a movement of TM5 away from TM3. The structures
of rhodopsin in an active conformation [52,53,60–63] have shown the
larger-scale conformational rearrangements related to the transition
to the Meta II states.
Different parameters can be used to deﬁne an active state from the
structural point of view. The most common is the large-scale displace-
ment (7 Å) of the cytoplasmic side of TM6, observed ﬁrst by electron
paramagnetic resonance [64] and later conﬁrmed in the active struc-
tures of rhodopsin [52,53,60–63] and the β2 adrenergic receptorFig. 3. Transition from the inactive dark state to lumirhodopsin results in an increase in the vo
conformation of Met207(5.42) (circle in the center panel). At this stage there is also a small rel
in the opening of a passage towards the cytoplasmic side (circle in the right panel) that allows[33,65]. In the latter, this movement is larger (11–14 Å), possibly due
to the binding of intracellular partners (nanobody or G protein).
A second criterion to deﬁne an active state is the rearrangement of a
“transmission switch” in the TM3–TM5–TM6 interface near the binding
site. The inﬂuence of Leu125(3.40) on the structure of the proline-
induced distortion of TM5 was ﬁrst proposed for rhodopsin [47], and its
functional relevance in other GPCRs was conﬁrmed in the histamine H1
receptor [66]. The concerted action of this residuewith Phe261(6.44) dur-
ing activationwasﬁrst proposed for theβ2 adrenergic receptor [65], and a
comparative analysis of active structures leadus to suggest that this trans-
mission switch is a key element of activation and constitutes a common
themeofGPCR activation [48]. In summary, rearrangement of the packing
between Ile125(3.40), Pro215(5.50), Leu216(5.51) and Phe261(6.44)
leads to a weakening of the TM5–TM6 interface and local conformationallume of the binding pocket (orange surface), mainly due to the change in the side chain
ocation of Met86(2.53). In the transition to Meta II, a larger rearrangement in TM6 results
the relocation of water molecules.
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transmission switch is not activated in lumirhodopsin, so it must be trig-
gered in later stages of the activation pathway, possibly inMeta I. The res-
idues in the transmission switch are highly conserved in rhodopsin-like
GPCRs (Table 2). This suggests that the conformational changes in the
TM3–TM5–TM6 interface constitute a conserved activation route in
rhodopsin-like GPCRs.
The analysis of these two indicators of the active state (TM6 move-
ment and activation of the transmission switch in TM3–TM5–TM6) in
the recent structures of non-rhodopsin GPCRs bound to agonists
[33,65,67–73] allows us to hypothesize that some of these structures
correspond to intermediates along the activation pathway. Within the
framework of rhodopsin activation, a “true” active state (i.e. Meta II)
would have to meet the two criteria, while intermediate states, such
as Meta I, would only feature an activated transmission switch, without
the relocation of TM6.
The structures of β1 adrenergic receptor thermostabilized by muta-
genesis and bound to full and partial agonists [73] show small local
structural changes in the binding pocket, but they lack both the
rearrangement of the transmission switch (Table 2) and the larger
relocation of TM6. These structures correspond to the low-afﬁnity
non-signaling binding states, formed on initial agonist binding. In this
case, the mutations that increase the thermal stability of the protein
construct and allowed crystallization, have likely locked the receptor
in a conformational state that cannot easily proceed through activation.
Thus, in the framework of rhodopsin activation, they most closely re-
semble a lumirhodopsin-like state, with the agonists establishing a sim-
ilar weakening effect on interhelical interactions as the β-ionone
movement in lumirhodopsin.
The adenosine A2A receptor has been crystallized in complex with
agonists as a fusion proteinwith T4 lysozyme [72] and thermostabilized
by mutagenesis [71]. Both structures feature an activated transmission
switch (Table 2), similarly to the active structures of rhodopsin and β2
adrenergic receptor [48], but the movement of the cytoplasmic side of
TM6 is signiﬁcantly smaller (Fig. 4). Thus, the ligand-binding site and
the immediate vicinity correspond to an active state, but lysozyme
fusion and mutagenesis seem to have decoupled the agonist-induced
activation of the transmission switch from the full relocation of TM6
and opening of the G protein-binding site. We have hypothesized thatTable 2
Composition of the transmission switch in TM3–TM5–TM6 in GPCRs for which agonist-
bound structures have been solved. Green and red denote, respectively, active and inactive
conformations of the residues in the switch. The lower section shows the amino acid con-
servation in this position for Class A (rhodopsin-like) GPCRs. It is worth to note that in the
neurotensin NTS1 receptor positions 5.51 and, particularly, 3.40, there is a remarkably dif-
ferent composition (in italics). Position 5.51 in 5HT1B also differs from the general trend.
Rho
β1AR
β2AR
A2AR
5HT1B
5HT2B
NTS1R
Class A
3.40 5.50 5.51 6.44
L125
l129
l121
l92
l137
l143
A157
P215
P219
P211
P189
P220
P229
P249
L216
L220
L212
L190
T221
L230
M250
F261
F299
F282
F242
F323
F333
F317
I: 41% P: 77%
V: 21%
L: 19%
L: 45%
F: 14%
F: 80%
Y: 9%
V: 13%
M: 12%the agonist-bound A2A receptor structures resemble a Meta I-like inter-
mediate state that expresses some, but not all, of the conformational
changes associated to activation [48]. These structures are “further
down” in the activation pathway that in the case of β1 adrenergic recep-
tor, but do not seem to correspond to fully active states.
The neurotensin NTS1 receptor has been crystallized in complex
with the C-terminal portion of the cognate agonist neurotensin [69].
In this case, the protein was simultaneously thermostabilized by muta-
genesis and fused with T4 lysozyme. Despite being heavily engineered,
this structure presents many features of an active state. While there are
differences in the composition of the transmission switch (see Table 2),
the conformations of M250(5.51) and F317(6.44) correspond to an ac-
tive state. Also, TM6 is displaced to a similar degree than rhodopsin,
opening a cavity for G protein binding (Fig. 4). However, this cavity is
occluded by part of TM7. While this may be an artifact of the protein
construct, it leads the authors to conclude that this structure does not
represent the structure of a fully active receptor.
Finally, the serotonin 5HT1B and 5HT2B receptors have been crystal-
lized in complexwith the agonists ergotamine (5HT2B) and dihydroergot-
amine (5HT1B and 5HT2B), as fusion proteins with the apocytochrome
b(562)RIL [67,68]. In this case, the transmission switch (referred to as
the P–I–F motif by the authors) is only fully activated in 5HT1B, while
5HT2B presents an intermediate state (see Table 2). In both cases, the
cytoplasmic side of TM6 is only slightly rearranged, similarly to the
adenosine A2A receptor (Fig. 4). This may be due to the design of the
fusion protein, as BRIL forms continuous helical stretches with TM5 and
TM6, presumably hampering their rearrangement upon activation. In ad-
dition, in one of the 5HT1B structures, a loop of b(562)RIL directly contacts
the cytoplasmic surface of the receptor. It is thus very likely that these
constructs cannot be properly activated by agonists, and are trapped in
an intermediate active state, resembling Meta I.
In summary, several of the currently available agonist-bound GPCR
crystal structures do not feature all the structural features of an active
state (e.g. Meta II [52,61] or β2 adrenergic receptor in complex with a
nanobody [65] or a G protein [33]). The β1 adrenergic receptor seems
to be trapped in a very early intermediate, possibly resembling
lumirhodopsin. The A2A and serotonin receptors may resemble later in-
termediates, where some structural changes in the cytoplasmic side
have taken place, as in Meta I. The neurotensin NTS1 receptor features
a remarkably active-like conformation, but important distortions in
TM7 lead us to suggest that this receptor does not represent a fully-
active state.
5. Conclusions
The constant trickle of non-rhodopsin GPCR structures from 2007
(which seems it can become an avalanche soon) may have led some
GPCR researchers to think that we should fully embrace this new and
exciting structural information and leave rhodopsin behind. Good old
rhodopsin was crucial up to then, as it was the only GPCR for which
we had high resolution structural information, but now it seems many
have waved it goodbye or simply forgotten it. This may be partially
due to the fact that there has always been an invisible divide between
“rhodopsin people” and “non-rhodopsin people” in the GPCR ﬁeld. As
a scientist who has learned to have one foot in each side, I can say that
rhodopsin still has a lot to teach us about how GPCRs work.
In the Introduction I mentioned the “historic” reasons why rhodop-
sin has been a key player in this ﬁeld, and in this paper I described a few
examples on how useful information can be extracted from its struc-
tures. But rhodopsin is still at the forefront of some aspects in GPCR
research, for example in the study of the molecular basis of disease-
inducing mutations or of cellular signaling networks at a systems level.
Due to the key role of GPCRs in cellular physiology, mutations that
result in defective signaling are linked to more than 30 different
human diseases, such as diabetes insipidus, fertility disorders, hypo-
and hyperthyroidism, and carcinomas, and more than 700 of such
Fig. 4. Relative orientation of TM6 in the crystal structures of dark state inactive rhodopsin and agonist-bound GPCRs. In the adenosine A2A and serotonin 5HT2B receptors, the
rearrangement of the cytoplasmic side of TM6 compared to inactive rhodopsin is relatively modest (also in the serotonin 5HT1B receptor, not shown for clarity) Thus, this region may
resemble a Meta I-like state. While in the neurotensin NTS1 receptor TM6 resembles that of active rhodopsin, other structural features suggest that this structure also represent an inter-
mediate active state (see text).
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ed in the transmembrane bundle, and most likely disrupt the structure
or the dynamic properties of the receptor, which translates into
malfunction and ultimately into disease. In these cases, the structural
analysis of these mutants can lead to a better understanding of the mo-
lecular basis of the disease, and to the development of new therapeutic
strategies. Rhodopsin has been theﬁrst (and so far only) GPCR forwhich
the structure of a disease-related mutant (Gly90(2.57)-Asp) has been
solved [60]. This structure suggests the molecular mechanisms by
which this mutation destabilizes the inactive conformation while selec-
tively favoring a short-lived preactivated conformation, resulting in ret-
initis pigmentosa or congenital night blindness. Interestingly, this
mutation is located at the strong distortion in TM2 (Fig. 2) and creates
an unnatural salt bridge between TM2 and TM7. The mutant has a re-
duced arrestin binding [60], further suggesting the involvement of the
TM2/TM7 activation pathway in activation and, possibly, in biased sig-
naling [23].
At a completely different scale, it is increasingly clear that to fully
understand GPCR function at the cellular level, we need to unravel the
details of the signaling pathways to obtain a comprehensive view of
signal transduction. While this is an area of intense research [75], our
current understanding of GPCR signaling at a systems level is still rela-
tively limited [76–79]. To date, the most detailed and exhaustive
multiscale signal transduction network of a GPCR has been developed
for rhodopsin, offering a comprehensive view of signal transduction
and suggesting novel signaling routes to vesicular trafﬁcking and cyto-
skeleton dynamics [80].
Of course, there are still open questions in the ﬁeld of rhodopsin
structural biology that are relevant to GPCR research. For instance,
obtaining a high-resolution structure of the Meta I intermediate would
complete the structural picture of the rhodopsin activation cycle,
which would shed light into the sequence of conformational changes
that lead to the stabilization of the active state in rhodopsin-like
GPCRs. Also, it is presently unknown if the dissimilarity in the
rearrangement of TM6 between the structures of Meta II bound to the
GαCT peptide and the β2 adrenergic receptor bound to Gs (Fig. 4) is
due to a fundamental difference in the active conformation of these
two receptors, or they simply reﬂect the effects of the different binding
partners present in the crystal structures. While the rhodopsin–GαCT
peptide complexes feature all the properties of Meta II, they display a
narrower cytoplasmic opening than the active β2 adrenergic receptor.
Obtaining the structure of the complex between rhodopsin and
transducin, and comparison with the rhodopsin–GαCT peptide com-
plexes, would allow us to have a better understanding of the role of
ligand-induced conformational rearrangement of TM6 on the stabiliza-
tion of the complexwith theG protein. Finally, retinal proteins are likely
to play an important role in the development of X-ray free electron laser(XFEL) crystallography. The fast development of XFEL imaging tech-
niques have allowed the recent structural determination of amembrane
protein complex, photosystem I, bymerging data from thousands of dif-
fraction images from nanocrystals [81]. As obtaining large and well-
diffracting crystals of membrane proteins is particularly challenging,
XFEL crystallography represents a very exciting new approach with
the potential to revolutionize the ﬁeld of membrane protein structural
biology [82]. But, importantly, the use of an XFEL synchronized with
an optical pump laser can be used to obtain diffraction snapshots from
photoactivatable membrane proteins [83]. This technique opens the
door to time-resolved structural studies of retinal proteins, which
would allow us to obtain information of GPCR activation at very high
temporal and spatial resolutions.
In summary, rhodopsin remains a relevant player in the ﬁeld of
GPCR research, and it will likely remain so in the future. Deﬁnitely,
you can teach an old dog new tricks.Acknowledgements
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